Program
TCC1727
A development code. Also written as “TCC1727 tablet 90mg”, “TCC1727 tablet 120mg” and “TCC1727 tablet 160mg”.
In Sino Biopharmaceutical's pipeline, ATR选择性抑制剂
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 22 open or running | phase 2since Jul 14, 2023 | Jul 14, 2023 | Sep 30, 2028phase 2 · NCT07371663 |
- Named in Sino Biopharmaceutical’s own pipeline as
TCC1727
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2023First study: phase 2 study in Patients with Advanced Solid TumorsFirst studyNCT05970016 · 56 planned · China
- Dec 15, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07371663 · 266 planned · China
Ahead
- Sep 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07371663
TargetBeta
“ATR选择性抑制剂”the company's pipeline, read by Claude · source
Other programs on ATR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ceralasertibrule | AstraZeneca | phase 3 | 16 |
| FXS887rule | Fosun Pharma | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07371663Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Sep 30, 2028 | 266 |
| NCT05970016Patients with Advanced Solid Tumors · China | 2 | Recruiting | Jul 30, 2025 | 56 |
How it is read
Names in the registry
- “TCC1727 tablet 90mg”, 1 entry
- “TCC1727 tablet 120mg”, 1 entry
- “TCC1727 tablet 160mg”, 1 entry
- “TCC1727 tablet(1)”, 1 entry
- “TCC1727 tablet(2)”, 1 entry
Codes read as this program: TCC1727.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.